Literature DB >> 29209641

The folate cycle is a new metabolic weakness of cancer.

Derek Lee1, Carmen Chak-Lui Wong1,2.   

Abstract

Cancer cells harness nutrients to support its rapid proliferation through metabolic reprogramming. Our report identified folate cycle as a metabolic target in hepatocellular carcinoma. Folate cycle stagnation via inhibition of its mitochondrial folate enzyme methylenetetrahydrofolate dehydrogenase 1-like (MTHFD1L) greatly induced oxidative stress improving HCC cells' response to sorafenib.

Entities:  

Keywords:  Folate cycle; HCC; MTHFD1L; NADPH; metabolism; oxidative stress

Year:  2017        PMID： 29209641      PMCID： PMC5706950          DOI： 10.1080/23723556.2017.1327004

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate.

Authors:  Patrick S Ward; Craig B Thompson
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

Review 2.  Regulation of cancer cell metabolism.

Authors:  Rob A Cairns; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Cancer       Date:  2011-02       Impact factor: 60.716

3.  Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma.

Authors:  Derek Lee; Iris Ming-Jing Xu; David Kung-Chun Chiu; Robin Kit-Ho Lai; Aki Pui-Wah Tse; Lynna Lan Li; Cheuk-Ting Law; Felice Ho-Ching Tsang; Larry Lai Wei; Cerise Yuen-Ki Chan; Chun-Ming Wong; Irene Oi-Lin Ng; Carmen Chak-Lui Wong
Journal:  J Clin Invest       Date:  2017-04-10       Impact factor: 14.808

Review 4.  Modulation of oxidative stress as an anticancer strategy.

Authors:  Chiara Gorrini; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Drug Discov       Date:  2013-12       Impact factor: 84.694

5.  Production of large amounts of hydrogen peroxide by human tumor cells.

Authors:  T P Szatrowski; C F Nathan
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

6.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

7.  NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma.

Authors:  Robin Kit-Ho Lai; Iris Ming-Jing Xu; David Kung-Chun Chiu; Aki Pui-Wah Tse; Larry Lai Wei; Cheuk-Ting Law; Derek Lee; Chun-Ming Wong; Maria Pik Wong; Irene Oi-Lin Ng; Carmen Chak-Lui Wong
Journal:  Clin Cancer Res       Date:  2016-01-27       Impact factor: 12.531

8.  Transketolase counteracts oxidative stress to drive cancer development.

Authors:  Iris Ming-Jing Xu; Robin Kit-Ho Lai; Shu-Hai Lin; Aki Pui-Wah Tse; David Kung-Chun Chiu; Hui-Yu Koh; Cheuk-Ting Law; Chun-Ming Wong; Zongwei Cai; Carmen Chak-Lui Wong; Irene Oi-Lin Ng
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-25       Impact factor: 11.205

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  Quantitative flux analysis reveals folate-dependent NADPH production.

Authors:  Jing Fan; Jiangbin Ye; Jurre J Kamphorst; Tomer Shlomi; Craig B Thompson; Joshua D Rabinowitz
Journal:  Nature       Date:  2014-05-04       Impact factor: 49.962
  10 in total
  7 in total

1.  Relationship between folate concentration and expression of folate-associated genes in tissue and plasma after intraoperative administration of leucovorin in patients with colorectal cancer.

Authors:  Helena Taflin; Elisabeth Odin; Kristoffer Derwinger; Göran Carlsson; Bengt Gustavsson; Yvonne Wettergren
Journal:  Cancer Chemother Pharmacol       Date:  2018-09-29       Impact factor: 3.333

2.  Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer.

Authors:  Marie-Lisa Eich; Maria Del Carmen Rodriguez Pena; Darshan Shimoga Chandrashekar; Alcides Chaux; Sumit Agarwal; Jennifer B Gordetsky; James E Ferguson; Guru P Sonpavde; George J Netto; Sooryanarayana Varambally
Journal:  Transl Oncol       Date:  2019-08-08       Impact factor: 4.243

3.  PHGDH as a mechanism for resistance in metabolically-driven cancers.

Authors:  Richa Rathore; Charles R Schutt; Brian A Van Tine
Journal:  Cancer Drug Resist       Date:  2020-09-17

Review 4.  Serine and one-carbon metabolisms bring new therapeutic venues in prostate cancer.

Authors:  Carlo Ganini; Ivano Amelio; Riccardo Bertolo; Eleonora Candi; Angela Cappello; Chiara Cipriani; Alessandro Mauriello; Carla Marani; Gerry Melino; Manuela Montanaro; Maria Emanuela Natale; Giuseppe Tisone; Yufang Shi; Ying Wang; Pierluigi Bove
Journal:  Discov Oncol       Date:  2021-10-27

5.  Mutations in SORL1 and MTHFDL1 possibly contribute to the development of Alzheimer's disease in a multigenerational Colombian Family.

Authors:  Johanna Alexandra Tejada Moreno; Andrés Villegas Lanau; Lucia Madrigal Zapata; Ana Yulied Baena Pineda; Juan Velez Hernandez; Omer Campo Nieto; Alejandro Soto Ospina; Pedronel Araque Marín; Lavanya Rishishwar; Emily T Norris; Aroon T Chande; I King Jordan; Gabriel Bedoya Berrio
Journal:  PLoS One       Date:  2022-07-29       Impact factor: 3.752

Review 6.  Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy.

Authors:  Yueming Zhu; Angela Elizabeth Dean; Nobuo Horikoshi; Collin Heer; Douglas R Spitz; David Gius
Journal:  J Clin Invest       Date:  2018-08-31       Impact factor: 14.808

7.  MTHFD1L-Mediated Redox Homeostasis Promotes Tumor Progression in Tongue Squamous Cell Carcinoma.

Authors:  Hao Li; Xiaoyan Fu; Fan Yao; Tian Tian; Chunyang Wang; Ankui Yang
Journal:  Front Oncol       Date:  2019-12-05       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.